Review · United States
Teriparatide
Reviewed on
Approval and product status
FDA-approved products exist for specific osteoporosis populations
The evidence applies to specific approved products and groups of people. Teriparatide evidence concerns approved drug products and labeled osteoporosis populations, not every product called PTH 1-34 or every type of fracture.
What was measured in people?
- Health results · Strong
- Randomized evidence supports vertebral and nonvertebral fracture-risk reduction in defined osteoporosis populations.
- Body changes · Strong
- Bone-turnover, exposure, and product-specific pharmacology are well characterized.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
The label has important limits on duration, risk factors, calcium, and monitoring. No dose, injection, or off-label fracture-healing instructions are provided.
Still unknown: This evidence does not prove faster healing for every new fracture, universal benefit in athletes, or safety outside monitored prescription use.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Products in this review
These are selected records, not every product or form.
Forteo
- Ingredients and form
- Prefilled delivery device
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Osteoporosis uses in the high-fracture-risk populations defined in the product label.
Published label: 2024 label
Read the published Forteo FDA label (PDF)What the research shows
Controlled trials and approved labeling support fewer spine and non-spine fractures in defined osteoporosis groups at high fracture risk.
Read all Teriparatide fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 3 sources
- FORTEO (teriparatide) prescribing information
U.S. Food and Drug Administration · Drug label · 2024
Source accessed
- Parathyroid hormone for postmenopausal osteoporosis
PubMed · New England Journal of Medicine · Randomized trial · 2001
Source accessed
- Teriparatide and femoral-neck fracture healing
PubMed · Clinical Orthopaedics and Related Research · Randomized trial · 2016
Source accessed